Zura Bio Q2 FY26 net loss widens to $26.3 million; R&D expense more than doubled to $20.7 million
ZURA•Cash position and runway
Cash and cash equivalents rose to $205.1 million at June 30, 2026; cash runway is expected to extend through at least end-2028.
Phase 2 program updates and timeline
Enrollment was completed in Phase 2 TibuSHIELD (247 participants) and TibuSURE (91); topline data is expected in Q4 2026 and H1 2027.
Polymyalgia rheumatica was selected as tibulizumab’s third indication; Phase 2 NEXUS-PMR is planned to start by end-2026 following supportive FDA feedback.
Q2 loss widens as R&D spending rises
Zura Bio posted a Q2 net loss of $26.3 million, or $0.21 per share, widening from $16 million, or $0.17 per share, a year earlier.
R&D expense climbed to $20.7 million from year-on-year, driven by advancing Phase 2 tibulizumab programs.
